** Shares of life science firm Avantor AVTR.N down 16.1% at $13 in early trading
** Stock trading at its lowest since April 2020
** Co announces Michael Stubblefield to step down as CEO as soon as successor is found
** Posts Q1 net sales of $1.58 bln, slightly below estimate of $1.60 bln - data compiled by LSEG
** AVTR reports adj. EPS of 23 cents, matching analysts' expectations
** Fourteen of 24 brokerages rate the stock "buy" or higher, 10 "hold"; median PT is $21.50 - data compiled by LSEG
** Including day's move, AVTR down 26.4% YTD
(Reporting by Twesha Dikshit)
((Twesha.Dikshit@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.